Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide adjunctive therapy for primary generalized tonic-clonic seizures
ACTRN12608000096358Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in epilepsy, idiopathic epilepsy (IGE) and generalized tonic-clonic seizure (GTCS) comparing Zonisamide adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Decrease of seizure frequency. Started Feb 2008; status: terminated.
02
Drugs
zonisamide
03
Conditions
epilepsyidiopathic epilepsy (IGE)generalized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on ACTRN12608000096358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000096358.